Bivalent HPV Vaccine and Pregnancy: Reassuring Findings

Prior pooled studies of the bivalent human papillomavirus (HPV) vaccine showed a slightly increased risk for miscarriage among women who became pregnant within 90 days of immunization. Now, investigators have analyzed extended trial follow-up (goal, 6 additional years) supplemented by observation of an unvaccinated cohort. In the trial, women received either HPV vaccine or hepatitis A vaccine; after 4 years, those women randomized to hepatitis A vaccine also received HPV vaccine

Among 3394 pregnancies in HPV vaccinated women, 13.3% ended in miscarriage. In the subset of 381 pregnancies conceived within 90 days of immunization, the miscarriage rate was 13.1%. Among unvaccinated women, 12.8% miscarried (P=0.29). These results were unchanged af…